Evaxion scraps tumor vaccine to focus on brain cancer candidate
Fierce Biotech reports Evaxion scrapped its solid tumor vaccine program to focus on a Duke-partnered brain cancer candidate.
Evaxion is a clinical-stage biotechnology company developing AI-driven immunotherapies, including personalized cancer vaccines and vaccines targeting bacterial pathogens, using its proprietary AI platforms PIONEER and EDEN.
Fierce Biotech reports Evaxion scrapped its solid tumor vaccine program to focus on a Duke-partnered brain cancer candidate.